Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 06  •  04:00PM ET
17.00
Dollar change
+0.59
Percentage change
3.60
%
Index- P/E- EPS (ttm)-0.86 Insider Own89.25% Shs Outstand354.09M Perf Week1.80%
Market Cap6.02B Forward P/E21.11 EPS next Y0.81 Insider Trans0.00% Shs Float38.07M Perf Month-2.30%
Enterprise Value10.71B PEG1.05 EPS next Q0.36 Inst Own10.20% Short Float9.68% Perf Quarter8.07%
Income-305.00M P/S1.21 EPS this Y-15.62% Inst Trans0.09% Short Ratio9.93 Perf Half Y23.19%
Sales4.98B P/B0.94 EPS next Y51.47% ROA-2.23% Short Interest3.68M Perf YTD-0.47%
Book/sh18.16 P/C18.14 EPS next 5Y20.07% ROE-4.69% 52W High17.86 -4.82% Perf Year-4.23%
Cash/sh0.94 P/FCF- EPS past 3/5Y- - ROIC-2.69% 52W Low10.45 62.68% Perf 3Y-2.35%
Dividend Est.- EV/EBITDA18.79 Sales past 3/5Y8.36% 4.87% Gross Margin54.02% Volatility3.32% 2.51% Perf 5Y-
Dividend TTM- EV/Sales2.15 EPS Y/Y TTM17.53% Oper. Margin2.85% ATR (14)0.45 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.98 Sales Y/Y TTM6.23% Profit Margin-6.13% RSI (14)52.81 Recom2.44
Dividend Gr. 3/5Y- - Current Ratio1.51 EPS Q/Q-799.12% SMA200.13% Beta0.61 Target Price17.54
Payout- Debt/Eq0.77 Sales Q/Q7.11% SMA500.52% Rel Volume0.95 Prev Close16.41
Employees13500 LT Debt/Eq0.77 EarningsFeb 18 BMO SMA20016.29% Avg Volume370.99K Price17.00
IPOMay 06, 2022 Option/ShortYes / Yes EPS/Sales Surpr.12.85% 0.27% Trades Volume352,046 Change3.60%
Date Action Analyst Rating Change Price Target Change
Jan-05-26Downgrade Evercore ISI Outperform → In-line $18
Dec-11-25Upgrade Citigroup Neutral → Buy $20
Dec-02-25Upgrade Morgan Stanley Equal-Weight → Overweight $21
Oct-01-25Initiated Goldman Neutral $16
May-02-25Reiterated H.C. Wainwright Buy $20 → $15
Mar-28-25Downgrade Wells Fargo Overweight → Equal Weight $24 → $15
Dec-11-24Downgrade Citigroup Buy → Neutral $24 → $22
Dec-02-24Downgrade Morgan Stanley Overweight → Equal-Weight $19
Oct-15-24Upgrade Evercore ISI In-line → Outperform $19 → $25
Jul-10-24Initiated Raymond James Outperform $19
Jan-29-26 11:34PM
Jan-23-26 11:40AM
Jan-20-26 07:15AM
Jan-05-26 07:00AM
Jan-02-26 04:30PM
07:30AM Loading…
Dec-23-25 07:30AM
Dec-17-25 04:30PM
Dec-12-25 04:48PM
Dec-11-25 11:41AM
Dec-04-25 10:09PM
Dec-02-25 11:10AM
Nov-18-25 04:30PM
Nov-13-25 02:57PM
08:55AM
08:41AM
06:59AM Loading…
Nov-10-25 06:59AM
04:28AM
Nov-05-25 12:35AM
Nov-03-25 04:30PM
Oct-30-25 01:34AM
Oct-29-25 03:47PM
09:30AM
08:05AM
07:23AM
07:06AM
06:58AM
Oct-28-25 09:26AM
Oct-27-25 11:12PM
Oct-20-25 06:44PM
11:36AM
09:34AM Loading…
09:34AM
07:41AM
07:25AM
Oct-19-25 08:00PM
Oct-17-25 12:24PM
Oct-10-25 06:44PM
Oct-02-25 11:40AM
Oct-01-25 11:01AM
Sep-25-25 01:06PM
Sep-11-25 07:00AM
Sep-09-25 07:00AM
Sep-08-25 06:56PM
04:30PM
07:00AM
Sep-05-25 12:41AM
Aug-22-25 02:25PM
Aug-20-25 11:31PM
Aug-18-25 05:48PM
05:01PM
Aug-14-25 07:15AM
Aug-12-25 11:55PM
11:48PM
Aug-07-25 12:38AM
Jul-30-25 03:05PM
12:16PM
09:30AM
08:10AM
07:34AM
07:04AM
06:57AM
05:38AM
Jul-29-25 09:27AM
07:00AM
Jul-28-25 11:09PM
Jul-24-25 05:04AM
Jul-23-25 10:00AM
Jul-22-25 08:45AM
Jul-21-25 09:13AM
Jul-20-25 11:31PM
Jul-01-25 07:00AM
Jun-30-25 06:58AM
Jun-26-25 04:30PM
Jun-25-25 07:42AM
Jun-23-25 11:58AM
Jun-18-25 04:30PM
Jun-10-25 08:48AM
Jun-04-25 06:59AM
May-27-25 12:47PM
May-22-25 07:30AM
12:00AM
May-21-25 04:30PM
09:36AM
06:59AM
May-14-25 06:59AM
May-08-25 12:37AM
May-07-25 09:30AM
07:00AM
May-01-25 03:08AM
Apr-30-25 04:40PM
11:02AM
09:30AM
08:10AM
06:57AM
Apr-29-25 03:10AM
Apr-24-25 10:01AM
07:00AM
Apr-23-25 07:23PM
11:40AM
10:01AM
Apr-22-25 10:08AM
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SAUNDERS BRENT LCEO and Chairman of the BoardMay 22 '25Buy11.2822,000248,072719,156May 27 08:16 AM
VON ESCHENBACH ANDREW C.DirectorMay 02 '25Buy11.761,69519,92541,748May 06 04:30 PM